# Nuclide record f-18-flutemetamol (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/f-18-flutemetamol/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "f-18-flutemetamol" ;
  schema:name "Flutemetamol F-18"@en ;
  schema:alternateName "Vizamyl"@en, "Vizamyl" ;
  schema:description "A PET scan tracer used to check whether a patient's brain has amyloid plaques, the hallmark of Alzheimer's disease, and whether they can be treated with amyloid-lowering drugs."@en ;
  schema:url <https://nuclide.cc/drugs/f-18-flutemetamol/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=b3558f16-8f9a-4e55-8d9c-836427ebaa57&type=pdf>, <https://www.ema.europa.eu/en/documents/product-information/vizamyl-epar-product-information_en.pdf>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6281542/>, <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=308> ;
  nuclide:status "approved" ;
  nuclide:tag "amyloid PET", "diagnostic", "neurology" ;
  nuclide:modality "PET tracer" ;
  nuclide:approval "US 2013: PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adults with cognitive impairment being evaluated for AD and other causes of cognitive decline", "US 2025: Label update adding selection of patients indicated for amyloid beta-directed therapy", "EU 2014: Diagnostic use to help diagnose Alzheimer's disease and other causes of memory loss" ;
  nuclide:related <https://nuclide.cc/indications/alzheimers-disease/>, <https://nuclide.cc/drugs/f-18-florbetapir/>, <https://nuclide.cc/drugs/f-18-florbetaben/>, <https://nuclide.cc/companies/ge-healthcare/>, <https://nuclide.cc/isotopes/f-18/> .